citalopram- citalopram hydrobromide tablet, film coated
aurobindo pharma limited - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg - citalopram tablets are indicated for the treatment of major depressive disorder (mdd) in adults [see clinical studies (14)] . citalopram tablets are contraindicated in patients: - taking, or within 14 days of stopping, maois (including maois such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions (5.3), drug interactions (7)] . - taking pimozide because of risk of qt prolongation [see drug interactions (7)] . - with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. reactions have included angioedema and anaphylaxis [see adverse reactions (6.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/r
metoclopramide- metoclopramide hydrochloride injection, solution
fresenius kabi usa, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg in 2 ml - metoclopramide injection (metoclopramide hydrochloride, usp) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. metoclopramide injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. metoclopramide injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g. in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforati
metoclopramide- metoclopramide hydrochloride injection, solution
general injectables & vaccines, inc. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg in 1 ml - diabetic gastroparesis (diabetic gastric stasis). metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy. metoclopramide injection, usp is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. the prevention of postoperative nausea and vomiting. metoclopramide injection, usp is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. small bowel intubation. metoclopramide injection, usp may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. radiological examination. metoclopramide injection, usp may be used to stimulate gastric emptying and intestinaltransit of barium in cases where delayed emptying interferes with radiological examination of
metoclopramide- metoclopramide tablet
aphena pharma solutions - tennessee, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets, usp is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets, usp are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12 week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets, usp are indicated for the
mint-citalopram tablet
mint pharmaceuticals inc - citalopram (citalopram hydrobromide) - tablet - 20mg - citalopram (citalopram hydrobromide) 20mg - selective-serotonin reuptake inhibitors
mint-citalopram tablet
mint pharmaceuticals inc - citalopram (citalopram hydrobromide) - tablet - 40mg - citalopram (citalopram hydrobromide) 40mg - selective-serotonin reuptake inhibitors
mint-citalopram tablet
mint pharmaceuticals inc - citalopram (citalopram hydrobromide) - tablet - 10mg - citalopram (citalopram hydrobromide) 10mg - selective-serotonin reuptake inhibitors
ag-citalopram tablets
angita pharma inc. - citalopram (citalopram hydrobromide) - tablet - 10mg - citalopram (citalopram hydrobromide) 10mg - selective-serotonin reuptake inhibitors
ag-citalopram tablets
angita pharma inc. - citalopram (citalopram hydrobromide) - tablet - 20mg - citalopram (citalopram hydrobromide) 20mg - selective-serotonin reuptake inhibitors
ag-citalopram tablets
angita pharma inc. - citalopram (citalopram hydrobromide) - tablet - 40mg - citalopram (citalopram hydrobromide) 40mg - selective-serotonin reuptake inhibitors